First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
2 Primary · 4 Secondary · Reporting Duration: From initiation of any study treatment to death from any cause, assessed up to Year 15
80 Total Participants · 1 Treatment Group
Primary Treatment: Dose finding part · No Placebo Group · Phase 1 & 2
Age 18 - 80 · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: